Shift in Trends: Aging Consumers Adopt Preventative Measures for Heart Health
Industry insights show that heart health supplements are now evolving to provide more comprehensive coverage.
The top issues being addressed and prevented by Boomers are high blood pressure (67%), and high cholesterol (64%).¹
deaths worldwide each year are caused by cardiovascular disease according to the World Health Organization in 2022.²
The heart health supplement market is valused at $16.7 billion by 2033, growing at 4.5% CAGR.³
ANKASCIN® 568 act as cholesterol balance and HDL protecter⁴
ANKASCIN® 568, functioning via the PPARγ/Nrf2 pathways, enhances LDL receptor expression and facilitates HDL-C formulation and protect HDL-C from oxidation to increase the transport of LDL-C to the liver for metabolism.
ANKASCIN® 568 supports healthy blood lipid profiles
In a randomized, double-blind clinical study, study show that total cholesterol and LDL-C were significantly reduced by 11.9% and 19% after 4 weeks.⁵ Another human clinical trial which conducted in Tainjin, study shows that serum triglycerides was reduced by 25.3%.⁶
More research has shown that there is a recent trend emphasizing the quality of HDL-C is as important as quantity.
ANKASCIN® 568 increases HDL formulation
Study have shown that ANKASCIN® 568 increases HDL level by 42.35%⁷, which is assoiated with increased level of ApoA1 expression for HDL synthesis by Monascin and Ankaflaivin.⁸ ⁹
ANKASCIN® 568 protects HDL from oxidation and degradaiotn
Besides HDL formulation, ANKASCIN® 568 activated Nrf2 to upregulate HO-1 expression to protect the structure of HDL, it also activate PPARγ to promote PON1 activity, which has been reported to have antioxidant properties, inhibiting HDL oxidation and degradation, thereby protecting HDL levels.⁹
ANKASCIN® 568 solves the leading factor, fatty plaque
ANKASCIN® 568, rich in Monascin and Ankaflavin, solves the leading factor, fatty plaque, indicating addressing the root cause of cardiovascular disease.¹⁰
ANKASCIN® 568 maintains healthy blood pressure¹¹
Clinical data show that ANKASCIN® 568 significantly reduced systolic and diastolic blood pressure from hypertension to pre-hypertension levels in just 4 weeks of administration. Similar results were maintained after 8 weeks of use.
ANKASCIN® 568 maintains healthy endothelial function
ANKASCIN® 568 increases NO production and decreases endothelin-1 expression to induce blood vessel relaxation to maintain healthy blood pressure levels.¹²
ANKASCIN® 568 improves vascular elastin stucture remodeling
ANKASCIN® 568 improves vascular elastin structure remodeling to manage blood pressure.¹³ ¹⁴
The recommended dose of ANKASCIN® 568 for a healthy adult is one unit daily according to specific requirements.
Benefits of ANKASCIN® 568 for Cardiovascular Health:
• Supports Cardiovascular Health*
• Maintain healthy cholesterol level*
• Matintain healthy endothelial function*
• Supports healthy blood lipid levels*
• Promotes healthy cholesterol levels already within normal range*
Your target audience who are
looking to maintain overall health/cardiovascular health:
seeking for metabolic support for menopause:
suffering from Statin’s side effect or trying to avoid the risk of interaction or excessive intake:
Market-Ready Formula Concepts
The Scientifically Proven, Market-Ready Solution to Set Your Products Apart and
Accelerate Your Success
ANKASCIN® 568 PRODUCT CONCEPTS
Ingredient:
ANKASCIN® 568
Application:
ANKASCIN® 568 PRODUCT CONCEPTS
Ingredient:
ANKASCIN® 568
Application:
▪️ Regulation of Blood Lipids
Helps to lower total cholesterol in serum
Helps to lower triglycerides in serum
Helps to increase HDL and decrease LDL in the blood
▪️ Regulation of Blood Sugar
Assists in regulating blood sugar for those with high fasting blood glucose levels
▪️ Anti-Aging Function
Helps in delaying the aging process.
1. Hartman Group, Natural Product Insider
2. World Health Organization, Cardiovascular diseases, 2021
3. Persistence Market Research, Global heart health supplements market, 2023
4. Food Funct. 2017 Jun 1;8(6):2102-2109.
5. Food Drug Anal. 2018 Jan;26(1):393-400.
6. In-house study (Tianjin Clinical Trial)
7. In-house study (Applied for Taiwan FDA health food certificate)
8. J. Funct. Foods. 5 (2013) 434-443.
9. J Microbiol Immunol Infect. 2018 Feb;51(1):27-37.
10. J Agric Food Chem. 2013 Jan 9;61(1):143-50.
11. Chin J Physiol. 2017 Jun 30;60(3)158-165.
12. J Agric Food Chem. 2012 Feb 22;60(7):1666-72.
13. In-house study (vascular elastin structure remodeling)
14. J Agric Food Chem. 2009 Jun 10;57(11):5035-41.
The communication is intended for business-to-business information and not for the final consumer. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.